Dihydrofolate reductase inhibitors antimetabolites

Mammals must obtain their tetrahydrofolate requirements from their diet, but microorganisms are able to synthesize this material. This offers scope for selective action and led to the use of sulphanilamide and other antibacterial sulpha drugs, compounds which competitively inhibit dihydropteroate synthase, the biosynthetic enzyme incorporating p-aminobenzoic acid into the structure. These sulpha drugs thus act as antimetabolites of p-aminobenzoate. Specific dihydrofolate reductase inhibitors have also become especially useful as antibacterials,... 

DIHYDROFOLATE REDUCTASE INHIBITORS have as a target the enzyme dihydrofolate reductase, and are known as folate antagonists. These include anttcancer agents ( antimetabolites ) such as methotrexate, antibacterial AGENTS such as trimethoprim, and the antiprotozoals pyrimethamine and proguanil (which are used to treat malaria). Folate is required for synthesis of purine nucleotides, which in turn are essential for DNA synthesis and cell division. In mammals it is necessary to convert body folates, through two separate enzyme-catalysed reduction... 

However, in view of its apparent success, this work is bound to advance further our understanding of the modes of action and structure-activity relationships of non-classical antimetabolites, and to produce new leads for the rational design of future drugs for chemotherapy. It should be remembered that it was the rational approach , based on the concepts of antimetabolites and of dihydrofolate reductase inhibitors as chemotherapeutic agents, that has... 

A considerable number of enzymes occupy a central and crucial role in the activity of drugs. Dihydrofolate reductase, an enzyme involved in purine and amino acid biosynthesis, is the target of antibacterial sulfanilamides, which act both as bacteriostatics and antimalarials. These drugs act on the enzyme in different ways, some being so-called antimetabolites (i.e., reversible enzyme inhibitors). Some diuretics act on carbonic... 

Methotrexate, a common antimetabolite, was introduced several decades ago for the treatment of psoriasis and remains an effective therapeutic approach. It is a synthetic analogue of folic acid that acts as a competitive inhibitor of the enzyme dihydrofolate reductase, that is responsible for the conversion of dihydrofolate to tetrahydrofolate. Tetrahydrofolate is an essential cofactor for the synthesis of thymidy-late and purine nucleotides required for DNA and RNA synthesis. Methotrexate inhibits replication and function of T and B cells and suppresses secretion of various cytokines such as IL-1, IFN-y,... 

Dihydropteroate synthase Sporozoans (eg, plasmodium, toxoplasma, and eimeria species) lack the ability to utilize exogenous folate and therefore possess enzymes for its synthesis these enzymes can be inhibited by drugs. Sulfonamides, which are antimetabolites of PABA, inhibit dihydropteroate synthase. Sequential blockade ctin be achieved with a sulfonamide and an inhibitor of dihydrofolate reductase (eg, pyrimethamine) such drug combinations are effective in malaria and toxoplasmosis. 

Trimethoprim, however, is a competitive inhibitor of dihydrofolate reductase . The accumulation of dihydrofolate, through continuing biosynthesis and reoxidation of tetrahydrofolate, tends to increase the metabolite antimetabolite ratio and diminishes the effectiveness of the blockade. Conjoint application of a sulfonamide, however, removes the source of new dlhydrofolate and Improves the effectiveness of the inhibition. In practice the simultaneous use of the 2 inhibitors results in a 5-10-fold potentiation, broadening of the spectrum of action, a decreased liability to the development of resistance, and a conversion of bacteriostatic to bactericidal effects . 

---